Related Experiment Video

Updated: Dec 14, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

A Novel Mechanism to Induce BRCAness in Cancer Cells

Changmeng Cai1

  • 1Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts. changmeng.cai@umb.edu.

Cancer Research
|July 17, 2020
PubMed

Insights

Prolyl isomerase Pin1 regulates BRCA1 degradation, creating "BRCAness" in cancer cells. Inactivating Pin1 sensitizes cells to PARP inhibitors, offering new therapeutic strategies for BRCAness-related cancers.

Area of Science:

  • Molecular biology
  • Cancer research
  • DNA repair mechanisms

Background:

  • Germline mutations in BRCA1 or BRCA2 genes lead to homologous recombination repair deficiency, making cancer cells sensitive to PARP inhibitors.
  • "BRCAness" describes a state in wild-type BRCA1/2-expressing cells with defects in other DNA repair pathways, which can also lead to synthetic lethality when combined with PARP inhibition.

Purpose of the Study:

  • To investigate the role of prolyl isomerase Pin1 in regulating BRCA1 protein degradation following DNA double-strand breaks.
  • To determine if Pin1 inactivation can induce "BRCAness" and sensitize cancer cells to PARP inhibitor treatment.

Main Methods:

  • The study by Luo and colleagues focused on the regulatory mechanism of BRCA1 protein degradation.
  • Investigated the interaction between Pin1 and BRCA1 in response to DNA damage.
  • Assessed the impact of Pin1 inactivation on "BRCAness" and PARP inhibitor sensitivity in cancer cells.

Main Results:

  • A novel mechanism was identified where prolyl isomerase Pin1 regulates BRCA1 protein degradation after DNA double-strand breaks.
  • Inactivation of Pin1 was shown to establish a state of "BRCAness" in cancer cells.
  • This induced "BRCAness" sensitized cancer cells to PARP inhibitor treatment.

Conclusions:

  • Pin1 plays a critical role in the regulation of BRCA1 stability and DNA repair.
  • Targeting Pin1 offers a potential strategy to induce "BRCAness" and enhance the efficacy of PARP inhibitors in a broader range of cancers.

More Related Videos

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA108:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

15.0K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K